 | |
| Type | Aktiengesellschaft |
|---|---|
| WBAG: ICLL OTCQX: INRLY | |
| Industry | Biotechnology |
| Founded | 1998 |
| Defunct | 2013 |
| Fate | Merged with Vivalis SA |
| Successor | Valneva SE |
| Headquarters | , |
Key people | Thomas Lingelbach (CEO), Michel Gréco (Chairman of the supervisory board) |
| Products | Development of vaccines |
| Revenue | €34.2 million (2010)[1] |
 (€251.2 million) (2010)[1] | |
| (€255.2 million) (2010)[1] | |
| Total assets | €225.2 million (end 2010)[1] |
| Total equity | €121.1 million (end 2010)[1] |
Number of employees | 410 (average, 2010)[1] |
| Website | www |
Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. The company merged with Vivalis to form Valneva SE in 2012.[2] Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna.[3] It employs 400 people in Austria, Scotland and the United States.
History
It was founded in 1998 and focused on the research, development, and commercialization of vaccines and other biological products. Intercell AG's products were used to prevent and treat a variety of infectious diseases, including hepatitis B, Japanese encephalitis, and pneumonia. In 2012, Intercell AG merged with Vivalis SE, a French biotech company, to form Valneva.[4]
It has been listed on the Vienna Stock Exchange since February 28, 2005. In 2008, Intercell signaled its intent to acquire Maryland-based Iomai, a developer of needle-free vaccination technology.[5][6]
Intercell cooperates with pharmaceutical companies like Novartis, Merck and Sanofi-Aventis on vaccine production.
The most important projects of Intercell are:
- Vaccine against Japanese encephalitis (approved in Europe, America and Australia)[7][8][9]
- Therapeutic vaccine against hepatitis C (in clinical phase II)[10]
- Antigen identification program and adjuvant technologies.
- Vaccine Enhancement Patch to improve prevention against pandemic influenza (in collaboration with U.S. Department of Health and Human Services, in clinical phase II)
References
- 1 2 3 4 5 6 "Annual Report 2010" (PDF). Intercell. Archived from the original (PDF) on 26 June 2011. Retrieved 3 May 2011.
- ↑ Carroll, John (17 December 2012). "Troubled Intercell throws in the towel, signs off on merger deal with Vivalis". Fierce Biotech. Retrieved 27 January 2018.
- ↑ "Research Institute of Molecular Pathology (IMP) - About the IMP > History". Research Institute of Molecular Pathology. Retrieved 2009-07-25.
- ↑ "The Dark Horse of the Vaccine Race May Be This French Biotech". Bloomberg.com. 2021-04-29. Retrieved 2023-01-09.
- ↑ Fox, Maggie; Grenon, Andre (2008-05-12). "Austrian vaccine maker Intercell buys Iomai". Reuters. Archived from the original on 2011-06-20. Retrieved 2008-08-15.
- ↑ Staff (1 June 2008), "Intercell to Acquire Iomai for $189M", Genetic Engineering & Biotechnology News, News: Inside Industry, Mary Ann Liebert, Inc., vol. 28, no. 11, p. 14, ISSN 1935-472X
- ↑ "Intercell's Japanese Encephalitis Vaccine FDA approval". Medical News Today. 2009-03-31. Retrieved 2009-03-31.
- ↑ "Intercell's Japanese Encephalitis Vaccine EMEA approval for Europe". Intercell. 2009-04-02. Retrieved 2009-04-02.
- ↑ "Intercell's Japanese Encephalitis Vaccine Australian TGA approval". Intercell. 2009-01-23. Retrieved 2009-01-23.
- ↑ "Intercell Hepatitis C Vaccine Meets Primary Endpoints". FDA News. 2007-08-22. Retrieved 2008-08-15.
External links